![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright © 2009 The Author(s) Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum 1Centre de Recherche en Infectiologie et Division de Microbiologie, Université Laval, Québec, Canada, G1V 4G2 and 2BIOGEM, University of California, San Diego, CA 92093, USA *To whom correspondence should be addressed. Tel: Phone: +1 418 654 2705; Fax: +1 418 654 2715; Email: marc.ouellette/at/crchul.ulaval.ca Received October 21, 2008; Revised December 19, 2008; Accepted December 20, 2008. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Antimonials remain the first line drug against the protozoan parasite Leishmania but their efficacy is threatened by resistance. We carried out a RNA expression profiling analysis comparing an antimony-sensitive and -resistant (Sb2000.1) strain of Leishmania infantum using whole-genome 70-mer oligonucleotide microarrays. Several genes were differentially expressed between the two strains, several of which were found to be physically linked in the genome. MRPA, an ATP-binding cassette (ABC) gene known to be involved in antimony resistance, was overexpressed in the antimony-resistant mutant along with three other tandemly linked genes on chromosome 23. This four gene locus was flanked by 1.4 kb repeated sequences from which an extrachromosomal circular amplicon was generated in the resistant cells. Interestingly, gene expression modulation of entire chromosomes occurred in the antimony-resistant mutant. Southern blots analyses and comparative genomic hybridizations revealed that this was either due to the presence of supernumerary chromosomes or to the loss of one chromosome. Leishmania parasites with haploid chromosomes were viable. Changes in copy number for some of these chromosomes were confirmed in another antimony-resistant strain. Selection of a partial revertant line correlated antimomy resistance levels and the copy number of aneuploid chromosomes, suggesting a putative link between aneuploidy and drug resistance in Leishmania. INTRODUCTION The protozoan parasite Leishmania is the etiological agent of a group of diseases termed leishmaniasis. Human leishmaniasis has a prevalence of 12 million cases, an estimated population of 350 million at risk and an incidence of 2 million new cases annually (1). No effective vaccine is yet available against this parasite and its control relies primarily on chemotherapy. Pentavalent antimony containing compounds such as sodium stibogluconate (Pentostam) and N-methylglucamine (Glucantime) remain the mainstay against all forms of Leishmania infections (1), but their efficacy is threatened by antimony-resistant parasites now described on a frequent basis in several endemic regions (2–4). Other drugs include pentamidine and amphotericin B but severe side effects and high cost have limited their widespread use. The aminoglycoside paromomycin is now more frequently used (1,5,6) and the first oral drug miltefosine shows promising efficacy despite evidence suggesting that resistance could develop rapidly (7). Since there are few new drugs in the pipeline (5,8–11) and resistance to first-line drug(s) has a significant therapeutic impact on this important parasitic disease, a better understanding of the molecular and biochemical mechanisms leading to resistance is warranted. The mechanisms involved in antimony resistance in Leishmania are partly understood, at least in in vitro selected antimony-resistant strains. These are mainly associated with a reduced activation or an altered transport of the drug. Pentavalent antimony (SbV) is believed to be a prodrug that requires biological reduction to its trivalent form (SbIII) in either the host macrophages and/or the parasites to acquire antileishmanial activity [reviewed in (5,8)] and a decreased SbV reduction rate has been reported in sodium stibogluconate-resistant amastigotes (12). The uptake of SbIII in Leishmania has been shown to be mediated by aquaglyceroporins and downregulation of aquaglyceroporin 1 (AQP1) was associated with an increased SbIII resistance (13,14). Furthermore, an increased level of trypanothione (TSH), the main cellular thiol in Leishmania (15), has been observed in mutants selected for antimony resistance (16–21) and could help to restore thiol redox potential which is perturbed following antimony accumulation (22,23). Increased levels of TSH also allow for the formation of thiol adducts of antimony that are either detoxified by their transport inside an intracellular organelle by the ATP-binding cassette (ABC) transporter MRPA or extruded from the parasite by an unidentified plasma membrane efflux system. The increased expression of MRPA is often due to the amplification of its gene in antimony-resistant strains (16,24,25). Other genes and proteins including a heat-shock protein 70 (26), a heat-shock protein 83 (27), a protein of the leucine-rich repeats (LRRs) superfamily (28), an amplified DNA from field isolates (29), a tryparedoxin peroxidase (30) and a very large polypeptide (31) were also associated with an increased tolerance toward antimony in some parasites. Several, but not all, of the antimony resistance mechanisms identified while studying in vitro selected mutants were also found in resistant field isolates (2,22,32–36). Resistance to antimonials seems to implicate several mutational events co-existing within the same cell (8). Accordingly, the simultaneous analysis of the whole genome could provide useful information about the complex events leading to resistance to this class of drugs. Small targeted DNA microarrays have already shown their usefulness in studying drug resistance mechanisms in Leishmania (17,37,38). In order to study gene expression modulation associated with antimony resistance on a full-genomic scale, we have carried out a RNA expression profiling experiment comparing an antimony-sensitive (WT) and an antimony-resistant (Sb2000.1) strain of Leishmania infantum using recently generated whole-genome 70-mer oligonucleotide microarrays for Leishmania (39,40). These experiments pinpointed specific mechanisms and novel changes in ploidy (supernumerary chromosomes and monosomy) that were correlated to resistance. MATERIALS AND METHODS Cell lines Leishmania infantum promastigotes were grown at 25°C in SDM-79 medium supplemented with 10% heat-inactivated fetal bovine serum and 10 μg/ml hemin. The L. infantum wild-type (WT) strain (MHOM/MA/67/ITMAP-263), the L. infantum Sb2000.1 mutant (37) and the L. infantum Sb4000.4 mutant (38) selected for SbIII resistance have been described previously. The L. infantum Sb400.2 and Sb1000.3 mutants were selected from a cloned parental population using a stepwise selection until they were resistant to 400 and 1000 μM SbIII, respectively. The L. infantum Sb2000.1 mutant was grown in the absence of SbIII for 30 passages in order to obtain a (partial) revertant line. Leishmania promastigotes were transfected by electroporation as reported previously (41). Growth curves were obtained by measuring absorbance at 600 nm of a 200-μl culture aliquot at 72 h using an automated microplate reader. DNA manipulations Total DNA was isolated using DNAzol reagent (Invitrogen) as recommended by the manufacturer. For quantitative Southern blots, the genomic DNA was digested with BamHI and EcoRV and migrated overnight at 30 V in 0.7% agarose gels. Southern blots, hybridizations and washes were performed following standard protocols (42) and all probes were obtained by PCR. Densitometric analyses of Southern blots were performed using ImageQuant 5.2 (Molecular Dynamics). The pSPαNEOα-MRPA construct has been described previously (43). The LinJ32_V3.2190 inactivation cassette was generated using the folowing PCR primers: primer 1, 5′-GCTCTAGAAGCTCCTGCGGTTTGCCTAC and primer 2, 5′-CCGTTATTGTGCCGACTGCCGGATCCGGGTGCGGAGTATGAAGGATG to amplify a region of 600-bp upstream of the gene and primer 3, 5′-GGCAGTCGGCACAATAACGG; and primer 4, 5′-CCCAAGCTTGGGTGTCACGCAGCTCCTTG in order to amplify a DNA fragment of 600-bp downstream of the gene. The upstream and downstream fragments were fused by PCR using primers 1 and 4 and the resulting DNA fragment was cloned in the pGEM-T-easy vector leading to the pGEM-UP/DOWN-32 vector. The XbaI, BamHI and HindIII restriction sites are underlined in the primers. An α-NEO-α cassette was isolated from the vector pSP72 α-NEO-α by digestion with BamHI and cloned in a unique BamHI restriction site located between the upstream and downstream fragments in pGEM-UP/DOWN-32 leading to the pGEM-KO32NEO plasmid. The LinJ32_V3.2190 inactivation cassette was isolated from pGEM-KO32NEO by an XbaI-HindIII digest and transfected in L. infantum WT, Sb2000.1 and Sb2000.1rev as previously described. The integration of the inactivation cassette at the LinJ32_V3.2190 locus was confirmed by PCR using the primers 5′- CAATACGCACGATGCACAGG and 5′-ACAACGTCGAGCACAGCTGC, and by Southern blots. Genomic DNA labeling was performed as previously described (40). Microarray design RNA isolation and labeling Total RNA was isolated from 108 Leishmania cells during the mid-log phase of growth using the RNeasy Plus Mini Kit (Qiagen) as described by the manufacturer. The RNAs were treated with RNase-free DNAse I Turbo (Ambion) to avoid any genomic contamination. The quality and quantity of RNA were assessed using RNA 6000 Nano Assay chips on a Bioanalyzer 2100 (Agilent technologies). The major criterion for RNA integrity was the presence of three clear ribosomal peaks (18S, 24Sα and 24Sβ) and the absence of RNA degradation. Ten micrograms of RNA were converted to aminoallyl-dUTP incorporated cDNA using random hexamers (Roche) and the SuperScript III Rnase H-Reverse Transcriptase (Invitrogen). Aminoallyl-dUTP incorporated cDNAs were thereafter coupled to Alexa Fluor 555 or Alexa Fluor 647 following manufacturer recommendations. Fluorescent cDNAs were purified with MinElute Spin Column (Qiagen) and quantified spectrophotometrically. Microarrays hybridization Microarray data acquisition and analysis Detection of the Alexa Fluor 555 and Alexa Fluor 647 signals was performed on a G2565CA DNA microarray scanner (Agilent technologies) at a 5-μm resolution. The signal intensity data were extracted from the primary scanned images using the GenePix Pro 6.0 software (Axon Technologies). Raw data were imported and normalization and statistical analyses were performed in R 2.2.1 using the LIMMA (Linear Models for Microarray Data) 2.7.3 package (46–48) as previously described (40). Multiple testing corrections were done using the false discovery rate method with a threshold P-value of 0.05. Only genes statistically significant with an absolute log2-transformed expression ratio greater than 0.58 were considered as differentially expressed. GeneSpring GX 3.1 was used for the generation of the chromosome map of expression ratios. The entire dataset was deposited to GEO under the reference number series GSE9949. Real-time RT-PCR Three independent RNA preparations were used for each real-time PCR experiment. First-strand cDNA was synthetized from 10 μg of RNA using random hexamers (Roche) and the SuperScript III RNase H-Reverse Transcriptase (Invitrogen) according to the manufacturer recommendations. Equal amounts of cDNA were run in triplicate and amplified in 15 μl reactions containing 7.5 μl of 2X Universal PCR Master Mix (Applied Biosystems), 10 nM Z-tailed forward primer, 100 nM reverse primer, 250 nM Amplifluor Uniprimer probe (Chemicon) and 1 µl cDNA target. Mixtures were incubated at 50°C for 2 min, at 95°C for 4 min and then cycled 55 times at 95°C for 15 s and at 55°C for 30 s using an Applied Biosystems Prism 7900 Sequence Detector at the Gene Quantification Core Laboratory of the Centre de Génomique de Québec (https://genome.ulaval.ca/qrtpcr). No-template controls were used as recommended. Amplification was normalized to the LinJ18_V3.0630 and LinJ36_V3.0850 genes, for which a highly stable expression was noted in several conditions by different microarrays experiments, before quantities of target genes were calculated according to standard curves using the REST 2005 software (Corbett Life Science). Primers were designed using Primer Express 2.0 (Applied Biosystems). RESULTS Gene expression profiling in L. infantum antimony-resistant mutants The completion of the L. major (44) and L. infantum (45) genome sequences allowed the generation of full genome 70-mer oligonucleotides DNA microarrays suitable for genome-wide expression profiling analyses in L. major and L. infantum (39,40). The arrays were used to study gene expression modulation associated with antimony resistance in the L. infantum Sb2000.1 mutant. This mutant is highly resistant to SbIII compared to its parental sensitive WT strain (Figure 1
DNA microarrays data were confirmed by real-time quantitative RT-PCR (qRT-PCR) experiments performed on a set of 21 selected genes (19 test genes and 2 control genes) and the two techniques correlated, with only few discrepant results (Figure 3
Extrachromosomal circular amplification of a gene locus on chromosome 23 The data generated from the microarray hybridizations can be illustrated by a chromosome map representing gene expression levels on a genomic scale (Figure 4
Antimony resistance selection leads to aneuploidy The expression of whole chromosomes seemed to be modulated in L. infantum Sb2000.1, as suggested by the chromosome map of gene expression ratios (Figure 4
A correlation between aneuploidy and drug resistance has already been described in yeast (51). In order to verify if the aneuploidy observed in Sb2000.1 and Sb4000.4 could be associated with antimony resistance, a partial revertant line of Sb2000.1 (Sb2000.1rev) was generated by successive passages in the absence of antimony. The SbIII resistance level of the revertant line decreased in cells that have grown for passages in the absence of drug but never completely reverted to the parental wild-type level (Figure 1
DISCUSSION Microarrays monitoring gene expression are now being used for the study of various aspects of Leishmania. The initial studies have dealt with a limited number of genes but genome-wide surveys are now being reported (39,40,52–54). Gene expression studies using whole-genome 70-mer oligonucleotide microarrays revealed the complexity of the genotype associated with antimony resistance in the L. infantum Sb2000.1 mutant. Indeed, several genes showed a significant difference in expression compared to the parental sensitive WT strain, some of which were part of an extrachromosomal amplicon while others were located on aneuploid chromosomes. The set of differentially regulated genes between L. infantum WT and Sb2000.1 included two ABC protein-coding genes, LinJ11_V3.0040/ABCH1 and LinJ23_V3.0290/MRPA. The genome-wide survey reported here revealed that the overexpression of ABCH1 is due to an increase in the number of copies of chromosome 11. Furthermore, the microarrays were useful to map precisely the amplified region encoding MRPA and three other genes on chromosome 23. Homologous recombination events that occured between direct repeats that bordered this amplified locus were responsible for the generation of the circular amplicon isolated from Sb2000.1. Gene amplification through homologous recombination between repeated sequences is a common mechanism of drug resistance in Leishmania (24,25,49,50,55,56) and is probably a consequence of the lack of transcriptional control in trypanosomatid parasites (57). Indeed, gene-specific expression modulation happened only for a limited number of genes and genes with a substantial variation in RNA levels were part of an amplicon generated by DNA recombination events. Accordingly, repeated sequences may flank key drug resistance genes to allow their amplification under conditions where an increase of a specific protein is required. Consistent with this proposal, the direct repeats flanking the MRPA locus on chromosome 23 are conserved in L. infantum, L. major and L. braziliensis, despite 15 million years of divergence (58). It is plausible that Leishmania could resort to aneuploidy to modulate the expression of relevant genes in the absence of direct or inverted repeats in the vicinity of a resistance gene or if more than one gene on a particular chromosome is required to confer resistance. Indeed, analysis of our microarrays data showed that gene expression modulation of entire chromosomes (e.g chromosomes 1, 11, 12, 25 and 32) was associated with a concomitant change in ploidy in the Sb2000.1 antimony-resistant strain (Figures 6 A role for aneuploidy in Leishmania drug resistance is supported by the presence of similar changes in ploidy for two chromosomes in the independently selected Sb2000.1 and Sb4000.4 antimony-resistant strains (Figure 6 Finally, the LinJ05_V3.0830 gene encoding a methylthioadenosine phosphorylase (MTAP) was downregulated several folds in many independent L. infantum SbIII-resistant mutants (Figure 3 Overall, the whole-genome expression profiling experiments enabled the identification of several genotypic changes associated with antimony resistance in Leishmania. Although few genes identified in this study displayed a dramatic modulation in expression, the antimony-resistant phenotype may occur from the synergistic interactions of several genes. With the exception of MRPA, the expression of several genes known to be involved in antimonials resistance (see ‘Introduction’ section) was not modulated in the Sb2000.1 mutant, which suggests that several mechanisms can lead to resistance. The arrays also allowed the identification of two novel phenomenons, including partial haploidy and supernumerary chromosomes. Further work is required to isolate the putative resistance genes located on aneuploid chromosomes and should also reveal how widespread these changes in chromosome copy number in Leishmania isolates are. FUNDING CIHR group grant (to J.C. and M.O.) and operating grants (to M.O.); CIHR studentship (to P.L. and F.R.); Canada Research Chair in Medical Genomics (to J.C.) and Burroughs Wellcome Fund Scholar in Molecular Parasitology and holds the Canada Research Chair in Antimicrobial Resistance (M.O.). Funding for open access charge: CIHR. Conflict of interest statement. None declared. REFERENCES 1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005;366:1561–1577. [PubMed] 2. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006;3:e162. [PubMed] 3. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 1999;180:564–567. [PubMed] 4. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 2006;193:1375–1383. [PubMed] 5. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006;19:111–126. [PubMed] 6. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br. Med. J. 1998;316:1200–1205. [PubMed] 7. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 2003;278:49965–49971. [PubMed] 8. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Updat. 2004;7:257–266. [PubMed] 9. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother. 2005;6:2821–2829. [PubMed] 10. Berman J. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 2003;16:397–401. [PubMed] 11. Croft SL, Coombs GH. Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19:502–508. [PubMed] 12. Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 2001;276:3971–3976. [PubMed] 13. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 2004;279:31010–31017. [PubMed] 14. Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol. Microbiol. 2005;57:1690–1699. [PubMed] 15. Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol. 1992;46:695–729. [PubMed] 16. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 1997;16:3057–3065. [PubMed] 17. Guimond C, Trudel N, Brochu C, Marquis N, El Fadili A, Peytavi R, Briand G, Richard D, Messier N, Papadopoulou B, et al. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res. 2003;31:5886–5896. [PubMed] 18. Haimeur A, Brochu C, Genest P, Papadopoulou B, Ouellette M. Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol. Biochem. Parasitol. 2000;108:131–135. [PubMed] 19. Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, Ouellette M. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol. Microbiol. 1999;34:726–735. [PubMed] 20. Legare D, Papadopoulou B, Roy G, Mukhopadhyay R, Haimeur A, Dey S, Grondin K, Brochu C, Rosen BP, Ouellette M. Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania. Exp. Parasitol. 1997;87:275–282. [PubMed] 21. Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M, Rosen BP. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl Acad. Sci. USA. 1996;93:10383–10387. [PubMed] 22. Mandal G, Wyllie S, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. Parasitology. 2007;134:1679–1687. [PubMed] 23. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 2004;279:39925–39932. [PubMed] 24. Grondin K, Papadopoulou B, Ouellette M. Homologous recombination between direct repeat sequences yields P-glycoprotein containing amplicons in arsenite resistant Leishmania. Nucleic Acids Res. 1993;21:1895–1901. [PubMed] 25. Ouellette M, Hettema E, Wust D, Fase-Fowler F, Borst P. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. EMBO J. 1991;10:1009–1016. [PubMed] 26. Brochu C, Haimeur A, Ouellette M. The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite leishmania. Cell Stress Chaperones. 2004;9:294–303. [PubMed] 27. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol. Cell Proteomics. 2007;6:88–101. [PubMed] 28. Genest PA, Haimeur A, Legare D, Sereno D, Roy G, Messier N, Papadopoulou B, Ouellette M. A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in Leishmania infantum amastigotes. Mol. Biochem. Parasitol. 2008;158:95–99. [PubMed] 29. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala azar field isolates. J. Infect. Dis. 2003;188:600–607. [PubMed] 30. Wyllie S, Vickers TJ, Fairlamb AH. Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob. Agents Chemother. 2008;52:1359–1365. [PubMed] 31. Choudhury K, Zander D, Kube M, Reinhardt R, Clos J. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int. J. Parasitol. 2008;38:1411–1423. [PubMed] 32. Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, Khanal B, Chappuis F, Dujardin JC. Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob. Agents Chemother. 2005;49:4616–4621. [PubMed] 33. Mukherjee A, Padmanabhan PK, Singh S, Roy G, Girard I, Chatterjee M, Ouellette M, Madhubala R. Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J. Antimicrob. Chemother. 2007;59:204–211. [PubMed] 34. Goyeneche-Patino DA, Valderrama L, Walker J, Saravia NG. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. Antimicrob. Agents Chemother. 2008;52:4503–4506. [PubMed] 35. Mittal MK, Rai S, Ashutosh, Ravinder, Gupta S, Sundar S, Goyal N. Characterization of natural antimony resistance in Leishmania donovani isolates. Am. J. Trop. Med. Hyg. 2007;76:681–688. [PubMed] 36. Singh N, Almeida R, Kothari H, Kumar P, Mandal G, Chatterjee M, Venkatachalam S, Govind MK, Mandal SK, Sundar S. Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. Parasitology. 2007;134:777–787. [PubMed] 37. El-Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Papadopoulou B, Legare D, Ouellette M. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob. Agents Chemother. 2005;49:1988–1993. [PubMed] 38. Leprohon P, Legare D, Girard I, Papadopoulou B, Ouellette M. Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot. Cell. 2006;5:1713–1725. [PubMed] 39. Rochette A, Raymond F, Ubeda JM, Smith M, Messier N, Boisvert S, Rigault P, Corbeil J, Ouellette M, Papadopoulou B. Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics. 2008;9:255. [PubMed] 40. Ubeda JM, Legare D, Raymond F, Ouameur AA, Boisvert S, Rigault P, Corbeil J, Tremblay MJ, Olivier M, Papadopoulou B, et al. Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol. 2008;9:R115. [PubMed] 41. Papadopoulou B, Roy G, Ouellette M. A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J. 1992;11:3601–3608. [PubMed] 42. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. New York: Cold Spring Harbor Laboratory Press; 1989. 43. Papadopoulou B, Roy G, Dey S, Rosen BP, Ouellette M. Contribution of the Leishmania P-glycoprotein-related gene ltpgpA to oxyanion resistance. J. Biol. Chem. 1994;269:11980–11986. [PubMed] 44. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, Sisk E, Rajandream MA, Adlem E, Aert R, et al. The genome of the kinetoplastid parasite, Leishmania major. Science. 2005;309:436–442. [PubMed] 45. Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, Peters N, Adlem E, Tivey A, Aslett M, et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 2007;39:839–847. [PubMed] 46. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004;3 Article 3. 47. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–2075. [PubMed] 48. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods. 2003;31:265–273. [PubMed] 49. Grondin K, Roy G, Ouellette M. Formation of extrachromosomal circular amplicons with direct or inverted duplications in drug-resistant Leishmania tarentolae. Mol. Cell. Biol. 1996;16:3587–3595. [PubMed] 50. Beverley SM. Gene amplification in Leishmania. Annu. Rev. Microbiol. 1991;45:417–444. [PubMed] 51. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science. 2006;313:367–370. [PubMed] 52. Holzer TR, McMaster WR, Forney JD. Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana. Mol. Biochem. Parasitol. 2006;146:198–218. [PubMed] 53. Leifso K, Cohen-Freue G, Dogra N, Murray A, McMaster WR. Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed. Mol. Biochem. Parasitol. 2007;152:35–46. [PubMed] 54. Saxena A, Lahav T, Holland N, Aggarwal G, Anupama A, Huang Y, Volpin H, Myler PJ, Zilberstein D. Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation. Mol. Biochem. Parasitol. 2007;152:53–65. [PubMed] 55. Liu X, Chang KP. The 63-kilobase circular amplicon of tunicamycin-resistant Leishmania amazonensis contains a functional N-acetylglucosamine-1-phosphate transferase gene that can be used as a dominant selectable marker in transfection. Mol. Cell. Biol. 1992;12:4112–4122. [PubMed] 56. Chow LM, Wong AK, Ullman B, Wirth DF. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii. Mol. Biochem. Parasitol. 1993;60:195–208. [PubMed] 57. Clayton CE. Life without transcriptional control? From fly to man and back again. EMBO J. 2002;21:1881–1888. [PubMed] 58. Lukes J, Mauricio IL, Schonian G, Dujardin JC, Soteriadou K, Dedet JP, Kuhls K, Tintaya KW, Jirku M, Chocholova E, et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA. 2007;104:9375–9380. [PubMed] 59. Cruz AK, Titus R, Beverley SM. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc. Natl Acad. Sci. USA. 1993;90:1599–1603. [PubMed] 60. Martinez-Calvillo S, Stuart K, Myler PJ. Ploidy changes associated with disruption of two adjacent genes on Leishmania major chromosome 1. Int. J. Parasitol. 2005;35:419–429. [PubMed] 61. Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, d’Enfert C, Berman J, Sanglard D. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell. 2007;6:1889–1904. [PubMed] 62. Doubre H, Cesari D, Mairovitz A, Benac C, Chantot-Bastaraud S, Dagnon K, Antoine M, Danel C, Bernaudin JF, Fleury-Feith J. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int. J. Cancer. 2005;113:568–574. [PubMed] 63. Tamar S, Papadopoulou B. A telomere-mediated chromosome fragmentation approach to assess mitotic stability and ploidy alterations of Leishmania chromosomes. J. Biol. Chem. 2001;276:11662–11673. [PubMed] 64. Yih LH, Ho IC, Lee TC. Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts. Cancer Res. 1997;57:5051–5059. [PubMed] 65. Wang Y, O’Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle. 2005;4:1847–1853. [PubMed] 66. Tseng YY, Yu CW, Liao VH. Caenorhabditis elegans expresses a functional ArsA. FEBS J. 2007;274:2566–2572. [PubMed] 67. McNicoll F, Muller M, Cloutier S, Boilard N, Rochette A, Dube M, Papadopoulou B. Distinct 3′-untranslated region elements regulate stage-specific mRNA accumulation and translation in Leishmania. J. Biol. Chem. 2005;280:35238–35246. [PubMed] 68. Bringaud F, Muller M, Cerqueira GC, Smith M, Rochette A, El-Sayed NM, Papadopoulou B, Ghedin E. Members of a large retroposon family are determinants of post-transcriptional gene expression in Leishmania. PLoS Pathog. 2007;3:1291–1307. [PubMed] 69. Subhi AL, Diegelman P, Porter CW, Tang B, Lu ZJ, Markham GD, Kruger WD. Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J. Biol. Chem. 2003;278:49868–49873. [PubMed] 70. Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, Slade D, Burchard J, Dow S, Ward TR, Kidd MJ, et al. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat. Genet. 2000;25:333–337. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
Lancet. 2005 Oct 29-Nov 4; 366(9496):1561-77.
[Lancet. 2005]PLoS Med. 2006 May; 3(5):e162.
[PLoS Med. 2006]J Infect Dis. 1999 Aug; 180(2):564-7.
[J Infect Dis. 1999]J Infect Dis. 2006 May 15; 193(10):1375-83.
[J Infect Dis. 2006]Clin Microbiol Rev. 2006 Jan; 19(1):111-26.
[Clin Microbiol Rev. 2006]Clin Microbiol Rev. 2006 Jan; 19(1):111-26.
[Clin Microbiol Rev. 2006]Drug Resist Updat. 2004 Aug-Oct; 7(4-5):257-66.
[Drug Resist Updat. 2004]J Biol Chem. 2001 Feb 9; 276(6):3971-6.
[J Biol Chem. 2001]J Biol Chem. 2004 Jul 23; 279(30):31010-7.
[J Biol Chem. 2004]Mol Microbiol. 2005 Sep; 57(6):1690-9.
[Mol Microbiol. 2005]Drug Resist Updat. 2004 Aug-Oct; 7(4-5):257-66.
[Drug Resist Updat. 2004]Nucleic Acids Res. 2003 Oct 15; 31(20):5886-96.
[Nucleic Acids Res. 2003]Antimicrob Agents Chemother. 2005 May; 49(5):1988-93.
[Antimicrob Agents Chemother. 2005]Eukaryot Cell. 2006 Oct; 5(10):1713-25.
[Eukaryot Cell. 2006]BMC Genomics. 2008 May 29; 9():255.
[BMC Genomics. 2008]Antimicrob Agents Chemother. 2005 May; 49(5):1988-93.
[Antimicrob Agents Chemother. 2005]Eukaryot Cell. 2006 Oct; 5(10):1713-25.
[Eukaryot Cell. 2006]EMBO J. 1992 Oct; 11(10):3601-8.
[EMBO J. 1992]J Biol Chem. 1994 Apr 22; 269(16):11980-6.
[J Biol Chem. 1994]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]Science. 2005 Jul 15; 309(5733):436-42.
[Science. 2005]Nat Genet. 2007 Jul; 39(7):839-47.
[Nat Genet. 2007]BMC Genomics. 2008 May 29; 9():255.
[BMC Genomics. 2008]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]BMC Genomics. 2008 May 29; 9():255.
[BMC Genomics. 2008]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]Bioinformatics. 2005 May 1; 21(9):2067-75.
[Bioinformatics. 2005]Methods. 2003 Dec; 31(4):265-73.
[Methods. 2003]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]Science. 2005 Jul 15; 309(5733):436-42.
[Science. 2005]Nat Genet. 2007 Jul; 39(7):839-47.
[Nat Genet. 2007]BMC Genomics. 2008 May 29; 9():255.
[BMC Genomics. 2008]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]Antimicrob Agents Chemother. 2005 May; 49(5):1988-93.
[Antimicrob Agents Chemother. 2005]Nucleic Acids Res. 1993 Apr 25; 21(8):1895-901.
[Nucleic Acids Res. 1993]EMBO J. 1991 Apr; 10(4):1009-16.
[EMBO J. 1991]Mol Cell Biol. 1996 Jul; 16(7):3587-95.
[Mol Cell Biol. 1996]Annu Rev Microbiol. 1991; 45():417-44.
[Annu Rev Microbiol. 1991]Science. 2006 Jul 21; 313(5785):367-70.
[Science. 2006]Eukaryot Cell. 2006 Oct; 5(10):1713-25.
[Eukaryot Cell. 2006]BMC Genomics. 2008 May 29; 9():255.
[BMC Genomics. 2008]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]Mol Biochem Parasitol. 2006 Apr; 146(2):198-218.
[Mol Biochem Parasitol. 2006]Mol Biochem Parasitol. 2007 Mar; 152(1):35-46.
[Mol Biochem Parasitol. 2007]Mol Biochem Parasitol. 2007 Mar; 152(1):53-65.
[Mol Biochem Parasitol. 2007]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]Proc Natl Acad Sci U S A. 1993 Feb 15; 90(4):1599-603.
[Proc Natl Acad Sci U S A. 1993]Int J Parasitol. 2005 Apr 1; 35(4):419-29.
[Int J Parasitol. 2005]Science. 2006 Jul 21; 313(5785):367-70.
[Science. 2006]Eukaryot Cell. 2007 Oct; 6(10):1889-904.
[Eukaryot Cell. 2007]Genome Biol. 2008; 9(7):R115.
[Genome Biol. 2008]FEBS J. 2007 May; 274(10):2566-72.
[FEBS J. 2007]J Biol Chem. 2005 Oct 21; 280(42):35238-46.
[J Biol Chem. 2005]PLoS Pathog. 2007 Sep 7; 3(9):1291-307.
[PLoS Pathog. 2007]J Biol Chem. 2003 Dec 12; 278(50):49868-73.
[J Biol Chem. 2003]Mol Microbiol. 1999 Nov; 34(4):726-35.
[Mol Microbiol. 1999]J Antimicrob Chemother. 2007 Feb; 59(2):204-11.
[J Antimicrob Chemother. 2007]